Jane L. Liesveld - Concepedia

Author

Jane L. Liesveld

University of Rochester Medical Center ORCID

Also Known As

Ayas, Mouhab, Christine Szych, Costa, Luciano J., Deol, Abhinav, Hematti, Peiman, J L Liesveld, J Liesveld, J. L. Liesveld, J. Liesveld, J.L Liesveld

436

Publications

14.4K

Citations

H-Index

125

Concepts

All Affiliations

University of Rochester Medical Center University of Rochester Medical College of Wisconsin Fred Hutch Cancer Center Dana-Farber Cancer Institute

About

Jane L. Liesveld is an author at University of Rochester Medical Center specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	67	4.9K
2	Health Sciences	18	24	2.8K
3	Natural Sciences	3	3	74
4	Engineering	1	1	29
5	Nursing	1	1	18

Jane L. Liesveld

160

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells Eleni D. Lagadinou, Alexander Sach, Kevin P. Callahan, Cell stem cell Hematological MalignancyCancer ResearchMedicineMixed-phenotype Acute LeukemiaCell Death	2013	1.3K
Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow Jessica L. Halliley, Christopher M. Tipton, Jane L. Liesveld, Immunity Human CellMedicineImmunologyHematologyBlood Cell	2015	510
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann, Blood	2001	445
Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma Steven M. Devine, Neal Flomenberg, David H. Vesole, Journal of Clinical Oncology	2004	415
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells Mónica L. Guzmán, Randall M. Rossi, Sundar Neelakantan, Blood	2007	407
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy Satu Mustjoki, Marja Ekblom, T. Petteri Arstila, Leukemia MedicineMalignant Blood DisorderImmunologyImmune Checkpoint InhibitorCell Biology	2009	316
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study Corey Cutler, Stephanie J. Lee, Sally Arai, Blood	2021	295
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group Jacob M. Rowe, Donna Neuberg, William R. Friedenberg, Blood	2003	275
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203) Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser, The Lancet Haematology Versus TacrolimusTransplantationImmunosuppressive TherapyImmunologyHematology	2019	274
Polyclonal Rabbit Antithymocyte Globulin Triggers B-Cell and Plasma Cell Apoptosis by Multiple Pathways Martin S. Zand, Thuong Vo, Jennifer Huggins, Transplantation	2005	233

Page 1